jofinЖурнал инфектологииJournal Infectology2072-6732IPO “АIDSSPbR"10.22625/2072-6732-2022-14-2-14-26jofin-1349Research ArticleОбзорReviewЭффективность и безопасность вакцин для профилактики новой коронавирусной инфекции на основе аденовирусных векторовEfficacy and safety of vector vaccines for the prevention of new coronavirus infectionХаритС. М.KharitS. M.

Харит Сусанна Михайловна – руководитель отдела профилактики инфекционных заболеваний; профессор кафедры инфекционных заболеваний у детей ФП и ДПО; д.м.н., профессор; тел.: 8(812)234-68-55

Санкт-Петербург

Saint-Petersburg

kharit-s@mail.ruФридманИ. В.FridmanI. V.

Фридман Ирина Владимировна – старший научный сотрудник отдела профилактики инфекционных заболеваний; к.м.н.; тел.: 8(812)234-68-55

Санкт-Петербург

Saint-Petersburg

fridiv@mail.ruДетский научно-клинический центр инфекционных болезней; Санкт-Петербургский государственный педиатрический медицинский университетРоссияPediatric Research and Clinical Center for Infectious Diseases; Saint-Petersburg State Pediatric Medical UniversityRussian FederationДетский научно-клинический центр инфекционных болезнейРоссияPediatric Research and Clinical Center for Infectious DiseasesRussian Federation2022130720221421426Copyright © Харит С.М., Фридман И.В., 20222022Харит С.М., Фридман И.В.Kharit S.M., Fridman I.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.niidi.ru/jofin/article/view/1349

В обзорной статье рассматриваются вакцины против SARS-CoV-2 на основе аденовирусных векторов, применяемые в настоящее время в мире. Описана концепция создания векторных вакцин. Представлены данные клинических исследований по эффективности и безопасности зарегистрированных аденовирусных векторных вакцин для профилактики новой коронавирусной инфекции. Подробно изложена частота развития серьезных нежелательных явлений после их применения. Помимо этого, определена клиническая эффективность векторных вакцин на изменяющиеся генотипы вируса COVID-19.

В обзоре проанализированы данные литературы о безопасности и эффективности применения векторных вакцин против коронавирусной инфекции.

Используемые в настоящее время векторные вакцины против новой коронавирусной инфекции достаточно безопасны и эффективны даже по отношению к новым генотипам вируса SARS-CoV-2.

The review article discusses vaccines against SARS-CoV 2 based on adenovirus vectors currently used in the world. The concept of creating vector vaccines is described. The data of clinical studies on the efficacy and safety of registered adenovirus-vector vaccines for the prevention of new coronavirus infection are presented. The frequency of serious adverse events after their use is described in detail. In addition, the clinical efficacy of vector vaccines for changing genotypes of the Covid 19 virus has been determined.

The review analyzes literature data on the safety and efficacy of vector vaccines against coronavirus infection.

The vector vaccines currently used against the new coronavirus infection are quite safe and effective even in relation to the new genotypes of the SARS-CoV 2 virus.

новая коронавирусная инфекцияаденовекторные вакциныэффективность и безопасностьnew coronavirus infectionadenovector vaccinesefficacy and safetyReferencesJackson, D.A.; Symons, R.H.; Berg, P. Biochemical method for inserting new genetic information into DNA of Simian Virus 40: Circular SV40 DNA molecules containing lambda phage genes and the galactose operon of Escherichia coli. Proc. Natl. Acad. Sci. USA 1972, 69, 2904–2909.Jackson, D.A.; Symons, R.H.; Berg, P. Biochemical method for inserting new genetic information into DNA of Simian Virus 40: Circular SV40 DNA molecules containing lambda phage genes and the galactose operon of Escherichia coli. Proc. Natl. Acad. Sci. USA 1972, 69, 2904–2909.T. Ura, K. Okuda, M. Shimada Developments in Viral Vector-Based Vaccines Vaccines 2014, 2(3), 624-641.T. Ura, K. Okuda, M. Shimada Developments in Viral Vector-Based Vaccines Vaccines 2014, 2(3), 624-641.Guideline on quality, non-clinical and clinical aspects of live recombinant viral vectored vaccines 24 June 2010 EMA/ CHMP/VWP/141697/2009 Committee for Medicinal Product for Human Use.Guideline on quality, non-clinical and clinical aspects of live recombinant viral vectored vaccines 24 June 2010 EMA/ CHMP/VWP/141697/2009 Committee for Medicinal Product for Human Use.Jun Chang Adenovirus Vectors: Excellent Tools for Vaccine Development Immune Netw. 2021 Feb;21(1).Jun Chang Adenovirus Vectors: Excellent Tools for Vaccine Development Immune Netw. 2021 Feb;21(1).K. Williams, A. R. Bastian, R. A. Feldman. Phase 1 Safety and Immunogenicity Study of a Respiratory Syncytial Virus Vaccine With an Adenovirus 26 Vector Encoding Prefusion F (Ad26.RSV.preF) in Adults Aged ≥60 Years The Journal of Infectious Diseases® 2020;222:979–88.K. Williams, A. R. Bastian, R. A. Feldman. Phase 1 Safety and Immunogenicity Study of a Respiratory Syncytial Virus Vaccine With an Adenovirus 26 Vector Encoding Prefusion F (Ad26.RSV.preF) in Adults Aged ≥60 Years The Journal of Infectious Diseases® 2020;222:979–88.Meeting of the Strategic Advisory Group of Experts on Immunization, 22–24 March 2021: conclusions and recommendations. Ebola vaccines.Р.203-205Meeting of the Strategic Advisory Group of Experts on Immunization, 22–24 March 2021: conclusions and recommendations. Ebola vaccines.Р.203-205Харченко, Е.П. Вакцины против Covid-19: сравнительная оценка рисков аденовирусных векторов / Е.П. Харченко // Эпидемиология и вакцинопрофилактика. – 2020. № 19 (5). – С. 4–17.Harchenko E. P. Vakciny protiv Covid-19: sravnitel’naya ocenka riskov adenovirusnyh vektorov. Epidemiologiya i Vakcinoprofilaktika. 2020; 19 (5): 4–17.Summary of product characteristics https://www.ema.europa.eu/en/documents/product-information/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-product-information_en.pdfSummary of product characteristics https://www.ema.europa.eu/en/documents/product-information/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-product-information_en.pdfS.E. Oliver, M. Wallace, I. See, S. Mbaeyi and et.Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine: Updated Interim Recommendations from the Advisory Committee on Immunization Practices — United States, December 2021 MMWR / January 21, 2022 / Vol. 71 / No. 3)S.E. Oliver, M. Wallace, I. See, S. Mbaeyi and et.Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine: Updated Interim Recommendations from the Advisory Committee on Immunization Practices — United States, December 2021 MMWR / January 21, 2022 / Vol. 71 / No. 3)Анализ последних данных о редких неблагоприятных случаях тромбоза после введения вакцин против COVID-19 компании AstraZeneca (Vaxzevria и Covishield) 16 апреля 2021 г. https://www.who.int/ru/news/item/16-04-2021-global-advisory-committee-on-vaccine-safety-(gacvs)-review-of-latest-evidence-of-rare-adverse-blood-coagulation-events-with-astra-zeneca-covid-19-vaccine-(vaxzevria-and covishield)Analiz poslednih dannyh o redkih neblagopriyatnyh sluchayah tromboza posle vvedeniya vakcin protiv COVID-19 kompanii AstraZeneca (Vaxzevria i Covishield) 16 aprelya 2021 g. https://www.who.int/ru/news/item/16-04-2021-global-advisory-committee-on-vaccine-safety-(gacvs)-review-of-latest-evidence-of-rare-adverse-blood-coagulation-events-with-astra-zeneca-covid-19-vaccine-(vaxzevria-and covishield)Updated Brighton Collaboration Case Definition for Thrombosis with Thrombocytopenia Syndrome (TTS) Robert T. Chen MD MA, Scientific Director, Brighton Collaboration https://brightoncollaboration.us/wp-content/uploads/2021/11/TTS-Updated-Brighton-Collaboration-Case-Defintion-Draft-Nov-11-2021.pdfUpdated Brighton Collaboration Case Definition for Thrombosis with Thrombocytopenia Syndrome (TTS) Robert T. Chen MD MA, Scientific Director, Brighton Collaboration https://brightoncollaboration.us/wp-content/uploads/2021/11/TTS-Updated-Brighton-Collaboration-Case-Defintion-Draft-Nov-11-2021.pdfJ.G. Rizk A.Gupta, P. Sardar, B. M. Henry, J.C. Lewin, G. Lippi, C.J. Lavie. Clinical Characteristics and Pharmacological Management of COVID-19 Vaccine–Induced Immune Thrombotic Thrombocytopenia with Cerebral Venous Sinus Thrombosis A Review JAMA Cardiol. 2021; 6(12):1451-1460. doi:10.1001/jamacardio.2021.3444J.G. Rizk A.Gupta, P. Sardar, B. M. Henry, J.C. Lewin, G. Lippi, C.J. Lavie. Clinical Characteristics and Pharmacological Management of COVID-19 Vaccine–Induced Immune Thrombotic Thrombocytopenia with Cerebral Venous Sinus Thrombosis A Review JAMA Cardiol. 2021; 6(12):1451-1460. doi:10.1001/jamacardio.2021.3444Y. Liu, Z. Shao, H. Wang SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia Thrombosis Research 209 (2022) 75–79.Y. Liu, Z. Shao, H. Wang SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia Thrombosis Research 209 (2022) 75–79.8 September 2021 corr1 COVID-19 vaccine safety update VAXZEVRIA AstraZeneca ABwww.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-vaxzevria-previously-covid-19-vaccine-astra-zeneca-8-september-2021_en.pdf8 September 2021 corr1 COVID-19 vaccine safety update VAXZEVRIA AstraZeneca ABwww.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-vaxzevria-previously-covid-19-vaccine-astra-zeneca-8-september-2021_en.pdfEMA 11 November 2021 COVID-19 vaccine safety update VAXZEVRIA AstraZeneca AB https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-vaxzevria-previously-covid-19-vaccine-astrazeneca-11-november-2021_en.pdfEMA 11 November 2021 COVID-19 vaccine safety update VAXZEVRIA AstraZeneca AB https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-vaxzevria-previously-covid-19-vaccine-astrazeneca-11-november-2021_en.pdfUpdates to the benefit/risk assessment for Janssen COVID-19 vaccines: Applying the Evidence to Recommendation Framework Sara Oliver, MD MSPH ACIP Meeting December 16, 2021.Updates to the benefit/risk assessment for Janssen COVID-19 vaccines: Applying the Evidence to Recommendation Framework Sara Oliver, MD MSPH ACIP Meeting December 16, 2021.I. See Updates on Thrombosis with Thrombocytopenia Syndrome (TTS) Advisory Committee on Immunization Practices (ACIP) Dec 16, 2021.I. See Updates on Thrombosis with Thrombocytopenia Syndrome (TTS) Advisory Committee on Immunization Practices (ACIP) Dec 16, 2021.J Robichaud, C. Côté, F. Côté Systemic capillary leak syndrome after ChAdOx1 nCOV-19 (Oxford–AstraZeneca) vaccination CMAJ, 2021, August, 30; 193:E1341-4. doi: 10.1503/cmaj.211212J Robichaud, C. Côté, F. Côté Systemic capillary leak syndrome after ChAdOx1 nCOV-19 (Oxford–AstraZeneca) vaccination CMAJ, 2021, August, 30; 193:E1341-4. doi: 10.1503/cmaj.211212А. M. Hause, J. Gee, J. Baggs, W.E. Abara, et al. COVID-19 Vaccine Safety in Adolescents Aged 12–17 Years — United States, December 14, 2020–July 16, 2021, Morbidity and Mortality Weekly Report / Vol. 70 / No. 31 August 6, 20211053-1058 MMWR / August 6, 2021 / Vol. 70 / No. 31А. M. Hause, J. Gee, J. Baggs, W.E. Abara, et al. COVID-19 Vaccine Safety in Adolescents Aged 12–17 Years — United States, December 14, 2020–July 16, 2021, Morbidity and Mortality Weekly Report / Vol. 70 / No. 31 August 6, 20211053-1058 MMWR / August 6, 2021 / Vol. 70 / No. 31E. Jane Woo, A. Mba-Jonas; R. B. Dimova, et al. Association of Receipt of the Ad26.COV2.S COVID-19 Vaccine With Presumptive Guillain-Barrй Syndrome, February-July 2021 JAMA. 2021;326(16):1606-1613. doi:10.1001/jama.2021.16496 Published online October 7, 2021E. Jane Woo, A. Mba-Jonas; R. B. Dimova, et al. Association of Receipt of the Ad26.COV2.S COVID-19 Vaccine With Presumptive Guillain-Barrй Syndrome, February-July 2021 JAMA. 2021;326(16):1606-1613. doi:10.1001/jama.2021.16496 Published online October 7, 2021Interim recommendations for the use of the Janssen Ad26.COV2.S (COVID-19) vaccine https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE-recommendation-Ad26.COV2.S-2021.1Interim recommendations for the use of the Janssen Ad26.COV2.S (COVID-19) vaccine https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE-recommendation-Ad26.COV2.S-2021.1ACIPPresentation,Dr.Alimchandani:July22,2021. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-07/02-COVID-Alimchandani-508.pdfACIPPresentation,Dr.Alimchandani:July22,2021. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-07/02-COVID-Alimchandani-508.pdfInterim recommendations for use of the ChAdOx1-S [recombinant] vaccine against COVID-19 (AstraZeneca COVID-19 vaccine AZD1222 Vaxzevria™, SII COVISHIELD™) https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE_recommendation-AZD1222-2021.1Interim recommendations for use of the ChAdOx1-S [recombinant] vaccine against COVID-19 (AstraZeneca COVID-19 vaccine AZD1222 Vaxzevria™, SII COVISHIELD™) https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE_recommendation-AZD1222-2021.1EMA Pharmacovigilance Risk Assessment Committee (PRAC) 5 – – 8 July 2021 meeting: Recommended an update to the product information to include a warning for Guillain-Barre syndrome (GBS) reported following vaccination with AstraZeneca COVID-19 Vaccine References: 06 Public Safety Update_VAXZEVRIA_14 July 2021 (europa.eu) Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 5-8 July 2021 | European Medicines Agency (europa.eu)EMA Pharmacovigilance Risk Assessment Committee (PRAC) 5 – – 8 July 2021 meeting: Recommended an update to the product information to include a warning for Guillain-Barre syndrome (GBS) reported following vaccination with AstraZeneca COVID-19 Vaccine References: 06 Public Safety Update_VAXZEVRIA_14 July 2021 (europa.eu) Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 5-8 July 2021 | European Medicines Agency (europa.eu)Sejvar JJ, Baughman AL, Wise M, Morgan OW. Population incidence of Guillain-Barré syndrome: a systematic review and meta-analysis. Neuroepidemiology. 2011; 36(2):123-33.Sejvar JJ, Baughman AL, Wise M, Morgan OW. Population incidence of Guillain-Barré syndrome: a systematic review and meta-analysis. Neuroepidemiology. 2011; 36(2):123-33.Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 10 -13January.2022 https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-10-13-january-2022Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 10 -13January.2022 https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-10-13-january-2022Technical report overview of the implementation of COVID-19 vaccination strategies and deployment plans in the EU/ EEA 11 November 2021 https://www.ecdc.europa.eu/sites/default/files/documents/COVID-19-vaccination-strategies-and-deployment-plans-Nov-2021.pdfTechnical report overview of the implementation of COVID-19 vaccination strategies and deployment plans in the EU/ EEA 11 November 2021 https://www.ecdc.europa.eu/sites/default/files/documents/COVID-19-vaccination-strategies-and-deployment-plans-Nov-2021.pdfD. Y Logunov, I.V Dolzhikova, D.V Shcheblyakov, A. I Tukhvatulin, O. V Zubkova, A.S Dzharullaeva, A., et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia, Lancet 2021; 397: 671–81 Published Online February 2, 2021 https://doi.org/10.1016/S0140-6736(21)00234-8D. Y Logunov, I.V Dolzhikova, D.V Shcheblyakov, A. I Tukhvatulin, O. V Zubkova, A.S Dzharullaeva, A., et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia, Lancet 2021; 397: 671–81 Published Online February 2, 2021 https://doi.org/10.1016/S0140-6736(21)00234-8M. Montalti1, G. Soldà, Z.Di Valerio, A. Salussolia,et al. ROCCA study protocol and interim analysis on safety of Sputnik V vaccine (Gam-COVIDVac) in the Republic of San Marino: an observational study using active surveillance Authors medRxiv preprint doi: https://doi.org/10.1101/2021.05.03.21256509; this version posted May 5, 2021)M. Montalti1, G. Soldà, Z.Di Valerio, A. Salussolia,et al. ROCCA study protocol and interim analysis on safety of Sputnik V vaccine (Gam-COVIDVac) in the Republic of San Marino: an observational study using active surveillance Authors medRxiv preprint doi: https://doi.org/10.1101/2021.05.03.21256509; this version posted May 5, 2021)V. Pagotto, A. Ferloni, M. Sorino. Аctive surveillance of the Sputnik V vaccine in health workers. medRxiv preprint. doi: https://doi.org/10.1101/2021.02.03.21251071.V. Pagotto, A. Ferloni, M. Sorino. Аctive surveillance of the Sputnik V vaccine in health workers. medRxiv preprint. doi: https://doi.org/10.1101/2021.02.03.21251071.Долгушина, Н.В. Вакцина Гам-КОВИД-Вак (Спутник V) не оказывает негативного влияния на овариальный резерв у женщин репродуктивного возраста / Н.В. Долгушина [и др.] // Акушерство и гинекология. – 2021. – № 7. С. 81–86.Dolgushina N.V., Drapkina YU.S., Krechetova L.V., Ivanec T.YU., Menzhinskaya I.V., Gus A.I., Bajramova G.R., Suhih G.T. Vakcina Gam-KOVID-Vak (Sputnik V) ne okazyvaet negativnogo vliyaniya na ovarial’nyj rezerv u zhenshchin reproduktivnogo vozrasta. Akusherstvo i ginekologiya. 2021; 7: 81-86.Адамян, Л.В. Вакцинация против COVID-19 не влияет на репродуктивное здоровье мужчин (по данным РНКсеквенирования) / Л.В. Адамян [и др.] // Проблемы репродукции. – 2021. – № 27 (5). – С. 8–12.L.V. Adamyan, V.I. Vechorko, V.V.Elagin, A.A.Dashko, D.A.Doroshenko, A.A.Stepanyan, I.V.Medvedeva, M.I.Sorokin, M.V.Suncova, V.O.Efimov, A.A. Buzdin. Vakcinaciya protiv COVID-19 ne vliyaet na reproduktivnoe zdorov’e muzhchin (po dannym RNK-sekvenirovaniya). Problemy reprodukcii. 2021;27(5):8–12.Campaña Nacional de Vacunación contra la COVID-19 10° Informe de vigilancia de seguridad en vacunas 02 de abril de 2021 Este informe fue realizado por profesionales de la DiCEI del Ministerio de Salud de la Nación en conjunto con la Comisión Nacional de Seguridad en Vacunas (CoNa-SeVa).Campaña Nacional de Vacunación contra la COVID-19 10° Informe de vigilancia de seguridad en vacunas 02 de abril de 2021 Este informe fue realizado por profesionales de la DiCEI del Ministerio de Salud de la Nación en conjunto con la Comisión Nacional de Seguridad en Vacunas (CoNa-SeVa).A. Barchuk, M. Cherkashin, A. Bulina, et al. Vaccine Effectiveness against Referral to Hospital and Severe Lung Injury Associatedwith COVID19: A Population Based Case Control Study in St. Petersburg, Russia medRxiv preprint doi: https://doi.org/10.1101/2021.08.18.21262065A. Barchuk, M. Cherkashin, A. Bulina, et al. Vaccine Effectiveness against Referral to Hospital and Severe Lung Injury Associatedwith COVID19: A Population Based Case Control Study in St. Petersburg, Russia medRxiv preprint doi: https://doi.org/10.1101/2021.08.18.21262065A. H. Rossi, D. S. Ojeda, A. Varese, et al. Sputnik V vaccine elicits seroconversion and neutralizing capacity to SARS-CoV-2 after a single dose/Cell Reports Medicine 2, 100359, August 17, 2021.A. H. Rossi, D. S. Ojeda, A. Varese, et al. Sputnik V vaccine elicits seroconversion and neutralizing capacity to SARS-CoV-2 after a single dose/Cell Reports Medicine 2, 100359, August 17, 2021.A. Gushchin, I. V. Dolzhikova, A. M. Shchetinin, et al. Neutralizing Activity of Sera from Sputnik V-Vaccinated People against Variants of Concern (VOC: B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3) and Moscow Endemic SARS-CoV-2 Variants Vaccines 2021, 9, 779.A. Gushchin, I. V. Dolzhikova, A. M. Shchetinin, et al. Neutralizing Activity of Sera from Sputnik V-Vaccinated People against Variants of Concern (VOC: B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3) and Moscow Endemic SARS-CoV-2 Variants Vaccines 2021, 9, 779.D. Lapa, D.Grousova, G. Matusali, S. Meschi , F. Colavita, et al. Retention of Neutralizing response against SARS-CoV-2 Omicron variant in Sputnik V vaccinated individuals medRxiv preprint; this version posted January 19, 2022.D. Lapa, D.Grousova, G. Matusali, S. Meschi , F. Colavita, et al. Retention of Neutralizing response against SARS-CoV-2 Omicron variant in Sputnik V vaccinated individuals medRxiv preprint; this version posted January 19, 2022.S. A. Halperin, L Ye, D. MacKinnon-Cameron, B. Smith, et al. Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial Lancet 2022; 399: 237–48 Published Online December 23, 2021 https://doi.org/10.1016/S0140-6736(21)02753-7S. A. Halperin, L Ye, D. MacKinnon-Cameron, B. Smith, et al. Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial Lancet 2022; 399: 237–48 Published Online December 23, 2021 https://doi.org/10.1016/S0140-6736(21)02753-7Weekly epidemiological update: Omicron variant of concern (VOC) – week 2 (data as of 13 January 2022) EU/EEA https://www.ecdc.europa.eu/en/news-events/weekly-epidemiological-update-omicron-variant-concern-voc-week-2-data-13-january-2022Weekly epidemiological update: Omicron variant of concern (VOC) – week 2 (data as of 13 January 2022) EU/EEA https://www.ecdc.europa.eu/en/news-events/weekly-epidemiological-update-omicron-variant-concern-voc-week-2-data-13-january-2022Results of COVID-19 Vaccine Effectiveness Studies: An Ongoing Systematic Review Forest Plots Updated November 4, 2021, Prepared by:International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health and World Health Organization.Results of COVID-19 Vaccine Effectiveness Studies: An Ongoing Systematic Review Forest Plots Updated November 4, 2021, Prepared by:International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health and World Health Organization.D. L. Burnett, K.J.L. Jackson, D.B. Langley et al., Immunizations with diverse sarbecovirus receptorbinding domains elicit SARS-CoV-2 neutralizing antibodies against a conserved site of vulnerability2021, Immunity 54, 2908–2921.D. L. Burnett, K.J.L. Jackson, D.B. Langley et al., Immunizations with diverse sarbecovirus receptorbinding domains elicit SARS-CoV-2 neutralizing antibodies against a conserved site of vulnerability2021, Immunity 54, 2908–2921.This article is part of a series of explainers on vaccine development and distribution. Learn more about vaccines – from how they work and how they’re made to ensuring safety and equitable access – in WHO’s. Vaccines Explained series. https://www.who.int/news-room/feature-stories/detail/the-effects-of-virus-variants-on-covid-19-vaccines.This article is part of a series of explainers on vaccine development and distribution. Learn more about vaccines – from how they work and how they’re made to ensuring safety and equitable access – in WHO’s. Vaccines Explained series. https://www.who.int/news-room/feature-stories/detail/the-effects-of-virus-variants-on-covid-19-vaccines.Preliminary data indicate COVID-19 vaccines remain effective against severe disease and hospitalisation caused by the Omicron variant News 11/01/2022.Preliminary data indicate COVID-19 vaccines remain effective against severe disease and hospitalisation caused by the Omicron variant News 11/01/2022.

The authors declare that there are no conflicts of interest present.